AnHeart Therapeutics is developing a pipeline of precision oncology therapeutics. Chief Business Officer and Co-founder Lihua Zheng provided an overview of company's strategy in response to emailed questions.
Randy Pritchard, Pillar Biosciences CEO, highlighted some of the progress the oncology solutions company has made in developing in-vitro diagnostics in response to emailed questions from MedCity News.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
U.S. government support can advance health breakthroughs and make a significant difference. I encourage you to support the creation of ARPA-H and to take specific actions to let your legislator know its importance.
When ChristianaCare's Graham Cancer Center saw that a significant number of its patients did not have a primary care provider, they decided to take action. Now, any patient that doesn't already have a PCP is connected to one onsite at the cancer center, expanding the care each patient receives.
Researchers have known for decades that viruses can beat back cancer. But it's been hard to design a virus that does the trick. A new wave of startups is optimistic they have found the keys.
Loki Therapeutics is advancing research that leverages the immune system's ability to recall childhood vaccinations and direct it against cancer. The company's lead therapy candidate could enter phase 1 clinical trials this year.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
Vaccines developed by Aivita Biomedical use a patient's own blood to attack cancer and Covid-19. But the company also offers a consumer skin-care product that it plans to begin selling more widely.
The latest funding brings total investment in the company to $750 million. The money has gone, in part, toward licensing of promising drug candidates in breast, lung and other cancers.
With a global epidemic of obesity and diabetes and their known relationship to cancer, researchers and oncologists are turning their attention to metabolic hormones as promising new targets for cancer treatment.
It is time to make it our collective mission to bring data automation to patient recruiting for clinical trials and not wait for a resolution of the pandemic to manage clinical trial disruption.
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.
Founded in 2014, MaaT Pharma is pushing two therapies through clinical trials that are designed improve survival for patients with blood cancers and other diseases. Despite high-profile hiccups, the field of microbiome therapy remains attractive to investors.
Unlike inherited genetic predispositions, accumulated genetic changes are the result of environmental influences, such as smoking, chemicals or ultra-violet radiation. A growing body of research links somatic changes to an increased likelihood of blood cancers and cardiovascular disease, both heart disease and stroke.
The San Diego-based biopharma firm has several oncology therapies in development and has partnered in the past with the likes of Astellas, BeiGene and Bristol-Myers Squibb.
With RWE helping to inform, guide, and refine ongoing protocols and pathways, we can battle Covid-19 and cancer together and be far better prepared in our response to the next pandemic.
Tumor boards can help physicians in developing countries get access to U.S. expertise and represent one way to democratize state-of-the-art care for cancer patients throughout the world.